Selumetinib (Koselugo) Reimbursement Review for Pediatric Neurofibromatosis Type 1
July 2023
in “
Canadian Journal of Health Technologies
”
Studysummary This review discusses selumetinib for treating symptomatic, inoperable plexiform neurofibromas in pediatric patients with neurofibromatosis type 1 and reports no new clinical results; it provides guidance for Canadian reimbursement decisions.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on canjhealthtechnol.ca →